Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A1 | P68400 | 10/20 | 0.50 |
| ▸ | PNMT | P11086 | 2/20 | 0.50 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.48 |
| ▸ | LOXL2 | Q9Y4K0 | 3/20 | 0.46 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.43 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.43 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.43 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.43 |
| ▸ | LOX | P28300 | 1/20 | 0.42 |
| ▸ | LOXL3 | P58215 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL42421 | 1.00 | CSNK2A1 (0.50) | CSNK2A1PNMTTAAR1LOXL2PIK3CA | |
| SCHEMBL793707 | 0.84 | TAAR1 (0.69) | PNMTTAAR1SLC6A3 | |
| Hydrochloric Acid SCHEMBL3271461 | 0.83 | TAAR1 (0.67) | PNMTTAAR1SLC6A3 | |
| SCHEMBL295912 | 0.82 | PNMT (0.48) | CSNK2A1PNMTTAAR1LOXL2SLC6A3 | |
| SCHEMBL20019811 | 0.81 | TAAR1 (0.53) | PNMTTAAR1PIK3CASLC6A4SLC6A3 | |
| Hydrochloric Acid SCHEMBL5958057 | 0.80 | CSNK2A1 (0.47) | CSNK2A1PNMTTAAR1LOXL2SLC6A3 | |
| Hydrochloric Acid SCHEMBL15518193 | 0.79 | TAAR1 (0.52) | PNMTTAAR1PIK3CASLC6A4SLC6A3 | |
| SCHEMBL923443 | 0.79 | ST14 (0.58) | LOXL2SLC6A4 | |
| SCHEMBL16388285 | 0.79 | PIK3CA (0.45) | PNMTTAAR1PIK3CASLC6A4SLC6A3 | |
| SCHEMBL1503218 | 0.79 | PIK3CA (0.45) | PNMTTAAR1PIK3CASLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4236950-A1 | N-LINKED ISOQUINOLINE AMIDES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | Merck Sharp & Dohme LLC (US) | 2023-09-06 | — | — | EP | disclosed |
| WO-2022195522-A1 | INHIBITORS OF ANO6 AND THEIR USES THEREOF | ILDONG PHARMACEUTICAL CO., LTD. (KR) | 2022-09-22 | — | — | WO | disclosed |
| US-11400082-B2 | Methods of treating elevated plasma cholesterol | Montréal Heart Institute (CA) | 2022-08-02 | — | — | US | disclosed |
| WO-2022157686-A1 | INHIBITORS OF ANOCTAMIN 6 PROTEIN AND USES THEREOF | ILDONG PHARMACEUTICAL CO., LTD. (KR) | 2022-07-28 | — | — | WO | disclosed |
| WO-2022093881-A1 | N-LINKED ISOQUINOLINE AMIDES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | MERCK SHARP & DOHME CORP. (US) | 2022-05-05 | — | — | WO | disclosed |
| CN-114286711-A | Bicyclic heterocyclic compounds as inhibitors of BCDIN3D activity | 风暴治疗有限公司 | 2022-04-05 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11400082-B2 | Methods of treating elevated plasma cholesterol | CETP, LDLR, APOB | CSNK2A1 1245/4885PNMT 2778/4885TAAR1 658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.